BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 32054921)

  • 21. Palmitoleic Acid Inhibits RANKL-Induced Osteoclastogenesis and Bone Resorption by Suppressing NF-κB and MAPK Signalling Pathways.
    van Heerden B; Kasonga A; Kruger MC; Coetzee M
    Nutrients; 2017 Apr; 9(5):. PubMed ID: 28452958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-κB pathways.
    Li CH; Xu LL; Jian LL; Yu RH; Zhao JX; Sun L; Du GH; Liu XY
    Int Immunopharmacol; 2018 May; 58():136-144. PubMed ID: 29587202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Agrimophol suppresses RANKL-mediated osteoclastogenesis through Blimp1-Bcl6 axis and prevents inflammatory bone loss in mice.
    Cao J; Wang S; Wei C; Lin H; Zhang C; Gao Y; Xu Z; Cheng Z; Sun WC; Wang HB
    Int Immunopharmacol; 2021 Jan; 90():107137. PubMed ID: 33199235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein kinase C inhibitor, GF109203X attenuates osteoclastogenesis, bone resorption and RANKL-induced NF-κB and NFAT activity.
    Yao J; Li J; Zhou L; Cheng J; Chim SM; Zhang G; Quinn JM; Tickner J; Zhao J; Xu J
    J Cell Physiol; 2015 Jun; 230(6):1235-42. PubMed ID: 25363829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kalkitoxin Reduces Osteoclast Formation and Resorption and Protects against Inflammatory Bone Loss.
    Li L; Yang M; Shrestha SK; Kim H; Gerwick WH; Soh Y
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ginsenoside Rb2 inhibits osteoclast differentiation through nuclear factor-kappaB and signal transducer and activator of transcription protein 3 signaling pathway.
    Cong F; Liu J; Wang C; Yuan Z; Bi L; Liang J; Su K; Qiu Y; Song T; Fan J; Chao G
    Biomed Pharmacother; 2017 Aug; 92():927-934. PubMed ID: 28605877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chlorogenic acid inhibits osteoclast differentiation and bone resorption by down-regulation of receptor activator of nuclear factor kappa-B ligand-induced nuclear factor of activated T cells c1 expression.
    Kwak SC; Lee C; Kim JY; Oh HM; So HS; Lee MS; Rho MC; Oh J
    Biol Pharm Bull; 2013; 36(11):1779-86. PubMed ID: 23985829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Picrasidine I from Picrasma Quassioides Suppresses Osteoclastogenesis via Inhibition of RANKL Induced Signaling Pathways and Attenuation of ROS Production.
    Kong L; Wang B; Yang X; Guo H; Zhang K; Zhu Z; Liu J; Hao D
    Cell Physiol Biochem; 2017; 43(4):1425-1435. PubMed ID: 29017159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GSH attenuates RANKL-induced osteoclast formation in vitro and LPS-induced bone loss in vivo.
    Han B; Geng H; Liu L; Wu Z; Wang Y
    Biomed Pharmacother; 2020 Aug; 128():110305. PubMed ID: 32485573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities.
    Joung YH; Darvin P; Kang DY; Sp N; Byun HJ; Lee CH; Lee HK; Yang YM
    PLoS One; 2016; 11(7):e0159891. PubMed ID: 27447722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. OA10 is a novel p38alpha mitogen-activated protein kinase inhibitor that suppresses osteoclast differentiation and bone resorption.
    Jiang T; Qin A; Shao ZY; Tian B; Zhai ZJ; Li HW; Zhu ZA; Dai KR; Ming HZ; Yu YP; Jiang Q
    J Cell Biochem; 2014 May; 115(5):959-66. PubMed ID: 24357524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss.
    Zhu M; Liu H; Sun K; Liu J; Mou Y; Qi D; Zhou C; Abudunaibi M; Tasiken B; Li J; Cheng H; Huang H
    Biomed Pharmacother; 2020 Mar; 123():109769. PubMed ID: 31846839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the alendronate and irradiation with a light-emitting diode (LED) on murine osteoclastogenesis.
    Sohn HM; Ko Y; Park M; Kim B; Park JE; Kim D; Moon YL; Lim W
    Lasers Med Sci; 2017 Jan; 32(1):189-200. PubMed ID: 27807651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways.
    He Y; Zhang Q; Shen Y; Chen X; Zhou F; Peng D
    Biochem Biophys Res Commun; 2014 Jul; 449(3):344-50. PubMed ID: 24845381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tereticornate A suppresses RANKL-induced osteoclastogenesis via the downregulation of c-Src and TRAF6 and the inhibition of RANK signaling pathways.
    Liu T; Jiang L; Xiang Z; Li J; Zhang Y; Xiang T; Wang W; Li X; Jia Y; Huang X; Lu X; Xu H; Wang X; Sheng J
    Biomed Pharmacother; 2022 Jul; 151():113140. PubMed ID: 35605290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Achyranthes bidentata polysaccharide suppresses osteoclastogenesis and bone resorption via inhibiting RANKL signaling.
    Song D; Cao Z; Huang S; Tickner J; Li N; Qiu H; Chen X; Wang C; Chen K; Sun Y; Dong S; Xu J
    J Cell Biochem; 2018 Jun; 119(6):4826-4835. PubMed ID: 29345352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diarylheptanoid from Curcuma comosa Roxb. suppresses RANKL-induced osteoclast differentiation by decreasing NFATc1 and c-Fos expression via MAPK pathway.
    Chawalitpong S; Sornkaew N; Suksamrarn A; Palaga T
    Eur J Pharmacol; 2016 Oct; 788():351-359. PubMed ID: 27523282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Madecassoside inhibits estrogen deficiency-induced osteoporosis by suppressing RANKL-induced osteoclastogenesis.
    Wang Q; Yao L; Xu K; Jin H; Chen K; Wang Z; Liu Q; Cao Z; Kenny J; Liu Y; Tickner J; Xu H; Xu J
    J Cell Mol Med; 2019 Jan; 23(1):380-394. PubMed ID: 30338925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Corylifol A protects against ovariectomized-induced bone loss and attenuates RANKL-induced osteoclastogenesis via ROS reduction, ERK inhibition, and NFATc1 activation.
    Xu Y; Song D; Lin X; Peng H; Su Y; Liang J; Hai N; Zhao J; Liu Q
    Free Radic Biol Med; 2023 Feb; 196():121-132. PubMed ID: 36649902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.